Mallinckrodt Announces Publication of Real-World Data on the Use of Extracorporeal Photopheresis (ECP) in Heart Transplant Patients vietreader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vietreader.com Daily Mail and Mail on Sunday newspapers.
Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the publication of findings from a retrospective, observational, single arm, European chart review study assessing the real-world use of extracorporeal photopheresis (ECP) and its impact on clinical outcomes in the modern era of heart transplantation.1 An online version of the data manuscript – the largest-known study of ECP in heart transplant patients – is currently published on the Journal of Hea
University Hospital Galway (UHG) has completed the final phase of an innovative clinical trial which reduces the hospitalisation rate for patients living with heart failure.
Results from the largest European and first multicenter, retrospective, observational chart review study investigating the real-world use of extracorporeal photopheresis (ECP) in heart transplant patients reinforce its use as a treatment for heart transplant rejection and prevention of rejection.
- Results from the largest European and first multicenter, retrospective, observational chart review study investigating the real-world use of ECP in heart transplant patients reinforce its